Effect of Ocrelizumab on B- and T-Cell Receptor Repertoire Diversity in Patients With Relapsing Multiple Sclerosis From the Randomized Phase III OPERA Trial.
Sarah A LaurentNicolas B StrauliErica L EggersHao WuBrady MichelStanislas DemuthArumugam PalanichamyMichael R WilsonMarina SirotaRyan D HernandezBruce Anthony Campbell CreeAnn E HermanH-Christian von BüdingenPublished in: Neurology(R) neuroimmunology & neuroinflammation (2023)
This is a substudy (BE29353) of the OPERA I (WA21092; NCT01247324) trial. Date of registration, November 23, 2010; first patient enrollment, August 31, 2011.